Soluble B‐cell Maturation Antigen in Multiple Myeloma and Correlation With Response to Therapy
Advances in Hematology · 2025-01 · 2025 (1)
DOI: 10.1155/ah/6664621 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advances in Hematology, online erschienen am 15.10.2025. Verfasst von Souvik Saha und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, sgpgi.ac.in. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sanjay Gandhi Postgraduate Institute of Medical Sciences.
Abstract (Originalsprache)
Aim
B‐cell maturation antigen (BCMA) is a nontyrosine kinase receptor expressed during plasma cell differentiation. Binding of ligands such as APRIL and BAFF to BCMA on malignant plasma cells leads to proliferation of tumor cells and plays an important role in the pathogenesis of multiple myeloma. Recent studies have explored the role of serum‐soluble BCMA (sBCMA) in assessing tumor load as well as monitoring of response. In this study, we aimed to detect serum sBCMA levels in newly diagnosed multiple myeloma patients as well as monitor the levels at follow‐up to correlate with response to therapy.
Methods
This was a prospective, longitudinal study conducted between March 2023 and July 2024. We documented the routine disease characteristics along with sBCMA levels at baseline and followed up sBCMA levels as a marker of therapy response.
Results
Baseline sBCMA levels were significantly higher in patients presenting with anemia and hypercalcemia and in patients having high‐risk cytogenetics. There was a trend toward correlation of sBCMA levels with bone marrow plasma cell percentage, β2‐microglobulin, and thrombocytopenia. We also found significant association of the sBCMA level with both ISS and R‐ISS staging. Furthermore, we assessed the response to therapy in terms of IMWG response criteria and sBCMA‐based response. The response according to conventional response criteria correlated significantly with sBCMA‐based response. We also found a significant association of decline in sBCMA levels to that of M band on response to therapy. There are certain advantages of using sBCMA as a response monitoring tool, such as in patients with renal impairment and in nonsecretory myeloma.
Conclusion
Our study provides an important insight into the relation of sBCMA to disease characteristics and the kinetics of decline in sBCMA on response to therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, sgpgi.ac.in.
ORCID-Profile: Souvik Saha, Khaliqur Rahman, Rajesh Kashyap
Förderung
- Sanjay Gandhi Postgraduate Institute of Medical Sciences
Zitieren
APA
Saha, S., Kakati, P., Singh, K., Singh, M. K., Rahman, K., Yadav, S., Chandra, D., Gupta, R., & Kashyap, R. (2025). Soluble B‐cell Maturation Antigen in Multiple Myeloma and Correlation With Response to Therapy. Advances in Hematology, 2025(1). https://doi.org/10.1155/ah/6664621
Vancouver
Saha S, Kakati P, Singh K, Singh MK, Rahman K, Yadav S, et al. Soluble B‐cell Maturation Antigen in Multiple Myeloma and Correlation With Response to Therapy. Advances in Hematology. 2025;2025(1). doi:10.1155/ah/6664621
BibTeX
@article{Saha2025,
author = {Saha, Souvik and Kakati, Prankrishna and Singh, Kulwant and Singh, Manish Kumar and Rahman, Khaliqur and Yadav, Sanjeev and Chandra, Dinesh and Gupta, Ruchi and Kashyap, Rajesh},
title = {Soluble B‐cell Maturation Antigen in Multiple Myeloma and Correlation With Response to Therapy},
journal = {Advances in Hematology},
year = {2025},
volume = {2025},
number = {1},
doi = {10.1155/ah/6664621}
}
EUVIMED